Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.64 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13765762 | 0.84 | KDM4E (0.67) | KDM4EPKMLMNAMEN1GAA | |
| SCHEMBL4106831 | 0.82 | KDM1A (0.76) | KDM4EPKMLMNAMEN1GAA | |
| SCHEMBL31681367 | 0.81 | KDM4E (0.62) | KDM4EPKMLMNAMEN1GAA | |
| SCHEMBL22104940 | 0.80 | LMNA (0.67) | KDM4EPKMLMNAMEN1KMT2A | |
| SCHEMBL15705234 | 0.80 | IDO1 (0.76) | KDM4EPKMLMNAMEN1GAA | |
| SCHEMBL4103788 | 0.79 | KDM4E (0.60) | KDM4EPKMLMNAMEN1GAA | |
| SCHEMBL4103783 | 0.79 | KDM4E (0.60) | KDM4EPKMLMNAMEN1GAA | |
| SCHEMBL19336603 | 0.79 | GPR27 (0.67) | KDM4EPKMLMNAMEN1GAA | |
| SCHEMBL7824415 | 0.79 | KDM4E (0.66) | KDM4EPKMLMNAMEN1GAA | |
| SCHEMBL8920527 | 0.79 | KDM4E (0.59) | KDM4EPKMLMNAMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318761-B2 | Substituted arylsulfonamides as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318761-B2 | Substituted arylsulfonamides as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318761-B2 | Substituted arylsulfonamides as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| EP-1991529-B1 | SUBSTITUTED ARYLSULFONAMIDES AS ANTIVIRAL AGENTS | AICURIS GMBH & CO KG (DE) | 2009-12-09 | — | — | EP | disclosed |
| EP-1991529-B1 | SUBSTITUTED ARYLSULFONAMIDES AS ANTIVIRAL AGENTS | AICURIS GMBH & CO KG (DE) | 2009-12-09 | — | — | EP | disclosed |
| US-20090176842-A1 | SUBSTITUTED ARYLSULFONAMIDES AS ANTIVIRAL AGENTS | AICURIS ANTI-INFECTIVE CURES GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176842-A1 | SUBSTITUTED ARYLSULFONAMIDES AS ANTIVIRAL AGENTS | AICURIS ANTI-INFECTIVE CURES GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176842-A1 | SUBSTITUTED ARYLSULFONAMIDES AS ANTIVIRAL AGENTS | AICURIS ANTI-INFECTIVE CURES GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| EP-1991529-A1 | SUBSTITUTED ARYLSULFONAMIDES AS ANTIVIRAL AGENTS | AiCuris GmbH & Co. KG (DE) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007101573-A1 | SUBSTITUTED ARYLSULFONAMIDES AS ANTIVIRAL AGENTS | AICURIS GMBH & CO. KG (DE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176842-A1 | SUBSTITUTED ARYLSULFONAMIDES AS ANTIVIRAL AGENTS | TPMT, ARSA, TYMP | KDM4E 2391/4885PKM 2923/4885ITGA1 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.